Skip to content

Study · Not a test of the peptide alone · 1996

2 results

Identification of ligand binding residues in extracellular loops of the melanocortin 1 receptor.

Chhajlani V, Xu X, Blauw J, Sudarshi S

Biochemical and biophysical research communications1 Feb 1996Cited by 23 (Europe PMC)

PMID8605020 (opens in a new tab)DOI10.1006/bbrc.1996.0266 (opens in a new tab)PepBankPUB-08605020
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan I (afamelanotide).

  1. 01LabNot a test of Melanotan I (afamelanotide) aloneIn vitro (cells)Activity measurement

    In COS-1 cells, replacing Asp184 with alanine in MC1R completely abolished binding of radiolabelled NDP-MSH.

    In plain wordsIn cells, changing one amino acid of the MC1R receptor completely stopped NDP-MSH from binding.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseNDP-MSH binding to the Asp184Ala MC1R mutant
    Study

    n: not reported in source

    COS-1 cells expressing MC1R mutants
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Substitution of Asp184 by alanine completely abolished the binding of radiolabelled NDP-MSH as well as ACTH, even though the mutated receptor could be detected on cell surface using anti MC1R specific polyclonal antiserum.
    1 context sentence
    Summary · context
    The mutant receptor DNAs were transiently expressed in COS-1 cells and their ability to bind [N1e4,D-Phe7]-alpha-MSH (NDP-MSH) was evaluated.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  2. 02LabNot a test of Melanotan I (afamelanotide) aloneIn vitro (cells)Activity measurement

    In COS-1 cells, mutations of Ser6, Glu269 and Thr272 in MC1R caused a considerable loss of affinity for radiolabelled NDP-MSH.

    In plain wordsIn cells, changing certain amino acids of the MC1R receptor greatly reduced how well NDP-MSH bound.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseNDP-MSH affinity for the Ser6, Glu269 and Thr272 MC1R mutants
    Study

    n: not reported in source

    COS-1 cells expressing MC1R mutants
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Mutations of Ser6, Glu269 and Thr272 resulted in a considerable loss of affinity for radiolabelled NDP-MSH
    1 context sentence
    Summary · context
    The mutant receptor DNAs were transiently expressed in COS-1 cells and their ability to bind [N1e4,D-Phe7]-alpha-MSH (NDP-MSH) was evaluated.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.